







an Open Access Journal by MDPI

# Molecular Mechanisms of the Polycomb Repressive Complex 2 (PRC2) and Its Role in Human Cancer

Guest Editor:

#### Dr. Robert Liefke

Institute of Molecular Biology and Tumor Research, University of Marburg, 35043 Marburg, Germany

Deadline for manuscript submissions:

closed (25 April 2024)

# **Message from the Guest Editor**

Dear Colleagues,

Polycomb repressive complex 2 (PRC2) is a conserved protein complex in multicellular organisms. It plays fundamental roles during developmental processes and has been implicated in many human diseases, such as cancer. PRC2 functions as a transcriptional repressor by depositing the repressive H3K27me3 mark. The precise functions of PRC2 in physiological and pathophysiological contexts remain incompletely understood. Components of the PRC2 core, but also many PRC2-associated proteins, such as PHF19, MTF2, JARID2 and EPOP, are commonly dysregulated in cancer, and play a role in various cancer types. A better understanding of their mechanistic functions will be essential to elucidate how they contribute to cancerogenesis.

This Special Issue entitled, "Molecular Mechanisms of the Polycomb Repressive Complex 2 (PRC2) and Its Role in Human Cancer", aims to provide a comprehensive overview of the most recent advances in this timely topic and a preview of future research directions and challenges to PRC2 and its role in human cancer.

Dr. Robert Liefke *Guest Editor* 













an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

# **Message from the Editor-in-Chief**

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

**Journal Rank:** JCR - Q2 (*Genetics & Heredity*) / CiteScore - Q2 (*Genetics*)

#### **Contact Us**